Capecitabine is a pyrimidine analog (pentoxycarbonyl-deoxy-cytosine nucleoside) that has anti-tumor activity to inhibit a variety of solid tumors, including breast and colon cancer. Capecitabine was developed by Roche. Its product, XELODA was approved to enter the Chinese market in 2001. By 2020, there are several manufacturers in the Capecitabine market in China.


According to CRI’s market research, the sales of Capecitabine in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on the hospital’s overall diagnosis and treatment services, sales in 2020 decreased to CNY 914 million, a year-on-year decrease of 9.31%. The CAGR of Capecitabine sales in the Chinese market from 2016 to 2020 is 1.21%.


CRI expects that with the easing of the COVID-19 pandemic, the sales of Capecitabine in the Chinese market will have a restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million, and the number of colon cancers reached 1.93 million, both of which were on the rise. The number of breast and colon cancers in China will be also on the rise in the future. Therefore, the sales volume of Capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase with the increase in the number of breast cancer and colon cancer patients in China. There is also room for sales to rise. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already reported for Capecitabine generic drug approval. In the next few years, more manufacturers will join the Chinese market. The sales volume and sales of Capecitabine in China are expected to rise.



Topics Covered:



  • -The impact of COVID-19 on China’s Capecitabine market

  • - Sales value of China’s Capecitabine 2016-2020

  • - Competitive landscape of China’s Capecitabine market

  • - Prices of Capecitabine in China

  • - Prices of Capecitabine in China by regions and manufacturers

  • - Analysis on factors affecting the development of China’s Capecitabine market

  • - Prospect of China’s Capecitabine market from 2021 to 2025